Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CencoraWBO:ABC +3.37%68 EV-to-EBIT is 17.96 as of Jul. 18, 2026, which is 5% above its 10-year median of 17.08. GuruFocus rates WBO:ABC with a GF Score™ of 68/100 and a GF Value™ of €259.89 (Fairly Valued). The stock has 1 warning sign investors should review. Among 93 Medical Distribution companies, Cencora ranks worse than 74.19% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cencora's Enterprise Value is €61,732 Mil.
Cencora's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €3,437 Mil. Therefore, Cencora's EV-to-EBIT for today is 17.96.
The historical rank and industry rank for Cencora's EV-to-EBIT or its related term are showing as below:
WBO:ABC'
s EV-to-EBIT Range Over the Past 10 Years
Min: -7.16 Med: 17.08 Max: 28.24
Current: 17.66
During the past 13 years, the highest EV-to-EBIT of Cencora was 28.24. The lowest was -7.16. And the median was 17.08.
WBO:ABC's EV-to-EBIT is ranked worse than 74.19% of 93
companies
in the Medical Distribution industry
Industry Median: 11.94
vs WBO:ABC: 17.66
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cencora's Enterprise Value for the quarter that ended in Mar. 2026 was €61,466 Mil.
Cencora's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,437 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cencora EV-to-EBIT Related Terms
Cencora EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cencora's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cencora's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cencora's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cencora's EV-to-EBIT falls into.
Cencora's current Enterprise Value is €61,732 Mil.
Cencora's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,437 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cencora (WBO:ABC) has a EV-to-EBIT of 17.96 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cencora and its competitors. This is near median its historical median of 17.08. According to the industry distribution chart, Cencora ranks #69 out of 93 companies in the Medical Distribution industry, placing it in the top 74.2%.
Is Cencora's EV-to-EBIT too high?
Cencora's current EV-to-EBIT of 17.96 is near median its 10-year median of 17.08. The Medical Distribution industry median EV-to-EBIT is 11.94. Cencora's value of 17.96 is 50.4% above this industry median. Based on the distribution chart, Cencora ranks #69 out of 93 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cencora has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's EV-to-EBIT compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #69 out of 93 companies for EV-to-EBIT. This places Cencora in the lower half of its industry. The industry median EV-to-EBIT is 11.94. Cencora's value of 17.96 is 50.4% above this benchmark. While the company's 10-year median is 17.08 vs. the industry median of 11.94, Cencora has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.94, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cencora's current EV-to-EBIT of 17.96 is 50.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cencora and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current EV-to-EBIT is 17.96, which is near median its own 10-year median of 17.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €259.89, compared to a current price of €273.30 — trading 5.2% above its estimated fair value. The current EV-to-EBIT is 17.96, which is near median its 10-year median of 17.08 and 50.4% above the Medical Distribution industry median of 11.94. Cencora's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cencora (WBO:ABC), the current EV-to-EBIT is 17.96 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (WBO:ABC) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be overvalued.
The current stock price of €273.30 is trading 5.2% above its estimated GF Value™ of €259.89.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for WBO:ABC:
EV-to-EBIT: 17.96 (near median its 10-year median of 17.08)
GF Value™: €259.89 vs. price of €273.30 (5.2% above fair value)
Industry Position: 50.4% above the Medical Distribution median (#69 of 93)
No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
68GF Score
Get the complete analysis for WBO:ABC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ABC has been successfully added to your 
